Scarica l'app Stockscreener
18.25
2.98%
-0.56
Dopo l'orario di chiusura:
18.25
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform (NASDAQ:TRVI) - Seeking Alpha
$Trevi Therapeutics (TRVI.US)$ lets punch through that BOLL band - Moomoo
Walleye Capital LLC Purchases Shares of 241,987 Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Stock Price Forecast. Should You Buy TRVI? - StockInvest.us
TRVI Maintained by Jones Trading -- Price Target Raised to $28.0 - GuruFocus
JonesTrading Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - MarketBeat
Does Wider Losses And New US$149.2m Shelf Offering Change The Bull Case For Trevi (TRVI)? - simplywall.st
HC Wainwright Issues Pessimistic Estimate for TRVI Earnings - MarketBeat
Sei Investments Co. Has $933,000 Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
What is HC Wainwright's Forecast for TRVI FY2030 Earnings? - MarketBeat
H.C. Wainwright Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - Moomoo
Trevi Therapeutics (TRVI) Short Interest & Short Float | Updated Aug 2026 $TRVI - MarketBeat
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $23 - Moomoo
1,525,314 Shares in Trevi Therapeutics, Inc. $TRVI Acquired by Assenagon Asset Management S.A. - MarketBeat
A Quick Look at Today's Ratings for Trevi Therapeutics(TRVI.US), With a Forecast Between $23 to $40 - Moomoo
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and Mail
Trevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and Mail
Q2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - Moomoo
Morgan Stanley Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $23 - Moomoo
Trevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - marketbeat.com
Trevi Therapeutics Q2 Earnings Call Highlights - MarketBeat
Trevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingView
Trevi Therapeutics Inc (TRVI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TRVI Maintains Rating by Oppenheimer -- Price Target Raised to $25.00 - GuruFocus
TRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocus
Oppenheimer Adjusts Trevi Therapeutics PT to $25 From $24, Maintains Outperform Rating - marketscreener.com
TREVI THERAPEUTICS, INC. : OPPENHEIMER RAISES TARGET PRICE TO $25 FROM $24 - Bitget
Cantor Fitzgerald Forecasts Strong Price Appreciation for Trevi Therapeutics (NASDAQ:TRVI) Stock - marketbeat.com
Raymond James raises Trevi Therapeutics price target on pipeline progress By Investing.com - Investing.com Australia
TRVI SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights - GuruFocus
Earnings call transcript: Trevi Therapeutics posts small Q2 2026 EPS miss - Investing.com UK
Trevi Therapeutics Inc (TRVI) (Q2 2026) Earnings Call Highlights: Advancing Phase 3 Pipeline ... - Yahoo Finance
Trevi Therapeutics (TRVI) Advances Clinical Trials Amid High Val - GuruFocus
Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q) - marketscreener.com
Trevi Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Trevi Q2 2026 Earnings: Higher Trial Spending Widens the Net Loss - TradingKey
Trevi Therapeutics, Inc. 2Q 2026: Net loss $17.8M, EPS $(0.11) — 10-Q Summary - TradingView
Trevi Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Trevi Therapeutics (NASDAQ: TRVI) funds late-stage cough trials with $318.9M - Stock Titan
Trevi Therapeutics reports Q2 2026 net loss of $17.8M; $318.9M cash and marketable securities - TradingView
Trevi Therapeutics faces earnings test as Haduvio trials advance By Investing.com - Investing.com Nigeria
Trevi Therapeutics faces earnings test as Haduvio trials advance - Investing.com
FMR LLC discloses 8.8% Trevi Therapeutics (TRVI) ownership in amended 13G - Stock Titan
$Trevi Therapeutics (TRVI.US)$ squeeze baby squeeze - Moomoo
Trevi Therapeutics (TRVI) Advances 4.75% as Biotech Momentum StrengthensOn Balance Volume - dars.gov.et
TRVI Q1 2026 Earnings: Wider Than Expected Loss of -$0.09 Per Share; Shares Dip 0.82%Earnings Preview - Vinanet
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Average Rating of "Buy" from Analysts - MarketBeat
Trevi Therapeutics sets Aug. 6 update on chronic-cough therapy - Stock Titan
Trevi Therapeutics (TRVI) to Post Earnings on Thursday - MarketBeat
Trevi Therapeutics Q2 Results: Earnings call set for Aug 6 - scanx.trade
Trevi Therapeutics to present at August biotech conferences on its chronic cough therapy Haduvio™ - Pluang
Trevi Therapeutics to Participate in Upcoming August Conferences - Yahoo Finance
Trevi's CEO and CFO join August biotech events in two states - Stock Titan
Trevi Therapeutics, Inc. Revenue Breakdown – NASDAQ:TRVI - TradingView
Trevi Therapeutics, Inc. $TRVI Shares Sold by Orbimed Advisors LLC - MarketBeat
Octagon Capital Advisors LP Reduces Stock Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Inc (TRVI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Trevi Therapeutics (TRVI) Climbs 3.34% as Stock Approaches Key Resistance LevelInstitutional Sentiment - dars.gov.et
Trevi Therapeutics Inc (TRVI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Trevi Therapeutics Inc (TRVI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Trevi Therapeutics Inc (TRVI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Trevi Therapeutics Inc (TRVI) Institutional Confidence - TradingKey
TradingKey - TradingKey
TRVI|Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
Trevi Therapeutics Inc|Price:17.535|Chg%:+0.355 - TradingKey
1.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):